On Monday, the American Academy of Neurology <a href="https://www.aan.com/PressRoom/Home/PressRelease/1364" target="_hplink">released preliminary data</a> from the drug's open label testing stage, a precursor to the controlled double-blind scientific trials currently underway. The research revealed that more than 50 percent of the 137 epileptic children and young adults continually treated with Epidiolex over a period of three months saw a reduction in their seizures.

&nbsp;

As Reported by: Huffington Post

http://www.huffingtonpost.com/2015/04/13/epidiolex_n_7055784.html